Mizuho upgrades Alector stock to Outperform on FTD drug prospects

Investing.com - Mizuho (NYSE:MFG) upgraded Alector Inc . (NASDAQ:ALEC) from Neutral to Outperform on Monday, raising its price target to $3.50 from $2.50, representing a 40% increase. The upgrade comes as the stock, currently trading at $1.76, has shown strong momentum with an 8.6% gain over the past week. According to InvestingPro analysis, the company appears undervalued based on its Fair Value estimates.

The upgrade comes as Alector approaches a significant milestone with upcoming Phase 3 clinical trial results for its lead drug candidate latozinemab in frontotemporal dementia (FTD), expected in the fourth quarter of 2025.

Mizuho increased its probability of success for latozinemab to 60% from 50% previously, citing recent key opinion leader feedback that was more positive than anticipated.

The research firm noted that Alector currently trades at a negative enterprise value despite having approximately $350 million in cash, with the company valued at roughly half that amount in the market.

Mizuho highlighted Alector’s cash runway extending to the second quarter of 2027 and several early-stage assets that provide additional pipeline opportunities beyond the upcoming FTD data readout. With earnings scheduled for July 31, InvestingPro subscribers can access 14 additional key insights and a comprehensive Pro Research Report for deeper analysis of Alector’s financial health and growth prospects.

In other recent news, Alector Inc. has seen a positive development as H.C. Wainwright & Co. raised its price target for the company from $7.00 to $10.00. This decision maintains a Buy rating for Alector’s shares. The upgrade follows encouraging results from Alector’s clinical trials for its lead drug candidate, latozinemab, also known as AL001. The INFRONT-3 trial is highlighted as a significant event for the company this year. Previous results from the 12-month INFRONT-2 trial showed promising outcomes, with symptomatic FTD-GRN patients receiving 60 mg/kg of latozinemab every four weeks. The treatment was observed to normalize PGRN levels, which are typically deficient in these patients. This development has been noted as a key catalyst for Alector, according to analysts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.